|
|
You are subscribed to receive research study announcements from the National Institutes of Health (NIH) Clinical Center. To learn more about this NIH study # 001522-H, or other studies, please call us at 833-JOIN-NIH
Pulmonary Arterial Hypertension (PAH) is associated with high blood pressure in the lungs due to narrowing of the small pulmonary arteries. The condition worsens over time. However, medications and oxygen therapy can help lessen the symptoms and improve the quality of life. The PAH team at the National Heart, Lung, and Blood Institute is testing the safety, tolerability, and effects of an investigational drug (ZMA001) that may help reduce blood pressure in the lungs to treat PAH. ZMA001 is in a class of drugs called monoclonal antibodies. The results of this work may determine an appropriate dose for PAH patients in the future.
You can participate if you are:
• 18-60 years old in good general health
• Willing to use an accepted method of contraception during the duration of the study
• Not pregnant or breastfeeding
What is involved:
• An initial screening visit
• An inpatient stay at the NIH Clinical Center to receive a single IV infusion
• Approximately 7 outpatient follow-up visits with blood work
• Study participation lasts about 16 weeks
Compensation up to $3,578 may be provided upon completion of study, based on study-related tasks.
|
|
|
